AIM ImmunoTech Files Q2 2024 10-Q

TL;DR

**AIM ImmunoTech dropped its Q2 10-Q. Check financials.**

AI Summary

AIM ImmunoTech Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Specific financial figures and operational details for the second quarter of 2024 are detailed within the filing.

Why It Matters

This filing provides investors with the latest financial performance and operational status of AIM ImmunoTech, crucial for understanding the company's trajectory in the biopharmaceutical sector.

Risk Assessment

Risk Level: medium — Biopharmaceutical companies often carry higher risk due to the nature of drug development, regulatory hurdles, and market competition.

Key Numbers

• 2024-06-30 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
• 2024-08-14 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240814 (date) — Filing date
• HEMISPHERX BIOPHARMA INC (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Indic

Filing Documents

• form10-q.htm (10-Q) — 1489KB
• ex10-4.htm (EX-10.4) — 12KB
• ex10-5.htm (EX-10.5) — 13KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-032355.txt ( ) — 7338KB
• aim-20240630.xsd (EX-101.SCH) — 51KB
• aim-20240630_cal.xml (EX-101.CAL) — 64KB
• aim-20240630_def.xml (EX-101.DEF) — 212KB
• aim-20240630_lab.xml (EX-101.LAB) — 405KB
• aim-20240630_pre.xml (EX-101.PRE) — 308KB
• form10-q_htm.xml (XML) — 1359KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2117 SW Highway 484 , Ocala FL 34473 (Address of principal executive offices) (Zip Code) (352) 448-7797 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share AIM NYSE American Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No 57,136,680 shares of common stock were outstanding, and no shares of series B preferred stock were outstanding as of August 12, 2024. PART I- FINANCIAL INFORMATION ITEM 1 : Financial Statements AIM IMMUNOTECH INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except for share and per share amounts) (Unaudited June 30, 2024 and Audited December 31, 2023) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 3,554 $ 5,439 Marketable securities 6,507 7,631 Funds receivable from New Jersey net operating loss — 1,184 Prepaid expenses and other current assets 300 302 Total current assets 10,361 14,556 Property and equipment, net 109 127 Right of use asset, net 700 697 Patent and trademark rights, net 2,491 2,313 Other assets 2,054 1,688 Total assets $ 15,715 $ 19,381 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,455 $ 6,443 Accrued expenses 799 1,986 Current portion of operating lease liability 234 223 Current portion of note payable, net 2,354 — Total current liabilities 8,842 8,652 Long-term liabilities: Operating lease liability 488 495 Note payable, net 283 — Total liabilities 9,613 9,147 Commitments and contingencies (Notes 12 and 13) - - Stockholders' equity: Series A Junior Participating Preferred Stock, $ 0.001 par value, 4,000,000 and 250,000 shares authorized as of June 30, 2024, and December 31, 2023, respectively: issued and outstanding – none — — Series B Convertible Preferred Stock, stated value $ 1,000 per share, 10,000 shares authorized; no issued and outstanding as of June 30, 2024 and 689 issued and outstanding as December 31, 2023 — 689 Common Stock, $ 0.001 par value, authorized shares - 350,000,000 ; issued and outstanding shares 57,136,680 and 49,102,484 as of June 30, 2024 and December 31, 2023, respectively 57 49 Additional paid-in capital 423,206 419,004 Accumulated deficit ( 417,161 ) ( 409,508 ) Total stockholders' equity 6,102 10,234 Total liabilities and stockholders' equity $ 15,715 $ 19,381 See accompanying notes to consolidated financial statements. 2 AIM IMMUNOTECH INC. AND SUBSIDIARIES Consolidated (in thousands, except share and per share data) (Unaudited) 2024 2023 2024 2023 Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Revenues: Clinical treatment programs - US $ 50 $ 42 $ 90 $ 91 Total Revenues 5

View Full Filing

View this 10-Q filing on SEC EDGAR